

References

- Akter, S., Magnus Bergström, L., Hansson, P., Hossain, S., & Larsson, P. (2026). Aggregation behavior of sodium caprate under different pH, concentration, and intestinal fluid conditions: a coarse-grained molecular dynamics study comparing Martini 2 and Martini 3. *Physical Chemistry Chemical Physics*, 28(22), 13514–13525. <https://doi.org/10.1039/d6cp00414h>
- Andersen, A., Knop, F. K., & Vilsbøll, T. (2021). A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. *Drugs*, 81(9), 1003–1030. <https://doi.org/10.1007/s40265-021-01499-w>
- Arwin, H. (2018). Adsorption of Proteins at Solid Surfaces. *Springer Series in Surface Sciences*, 31–48. https://doi.org/10.1007/978-3-319-75895-4_2
- Azman, M., Sabri, A. H., Anjani, Q. K., Mustaffa, M. F., & Hamid, K. A. (2022). Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery. *Pharmaceuticals*, 15(8), 975. <https://doi.org/10.3390/ph15080975>
- Baral, K. C., & Choi, K. Y. (2025). Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances. *Pharmaceutics*, 17(4), 397–397. <https://doi.org/10.3390/pharmaceutics17040397>
- Bardonnet, P.-L., Niu, Z., Pessi, J., Kazakou, M., Raptis, K., McCabe, R., Toftlev, A., Rebollo, R., Wang, Z., Fan, L., Mortensen, N. R., Bardtrum, L., Andersson, V., Wahlund, P.-O., Norrman, M., Benie, A. J., Wu, J. X., Sauter, M., Zara, D. L., & Christophersen, P. (2025). An effort to enhance the clinical translatability of caprate-based tablet formulations in gastric peptide delivery. *Drug Delivery and Translational Research*. <https://doi.org/10.1007/s13346-025-01978-7>
- Brunner, J., Ragupathy, S., & Borchard, G. (2021). Target specific tight junction modulators. *Advanced Drug Delivery Reviews*, 171, 266–288. <https://doi.org/10.1016/j.addr.2021.02.008>
- Collins, L., & Costello, R. A. (2024, February 29). *Glucagon-like peptide-1 receptor agonists*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK551568/>

- DeFronzo, R. A., Ferrannini, E., Groop, L., Henry, R. R., Herman, W. H., Holst, J. J., Hu, F. B., Kahn, C. R., Raz, I., Shulman, G. I., Simonson, D. C., Testa, M. A., & Weiss, R. (2015). Type 2 Diabetes Mellitus. *Nature Reviews Disease Primers*, 1(1). <https://doi.org/10.1038/nrdp.2015.19>
- Dhillon, S. (2018). Semaglutide: First Global Approval. *Drugs*, 78(2), 275–284. <https://doi.org/10.1007/s40265-018-0871-0>
- Dong, R., & Zeitler, J. A. (2022). Visualising liquid transport through coated pharmaceutical tablets using Terahertz pulsed imaging. *International Journal of Pharmaceutics*, 619, 121703–121703. <https://doi.org/10.1016/j.ijpharm.2022.121703>
- Farmaki, P., Damaskos, C., Garmpis, N., Garmpi, A., Savvanis, S., & Diamantis, E. (2020). Complications of the Type 2 Diabetes Mellitus. *Current Cardiology Reviews*, 16(4), 249–251. <https://doi.org/10.2174/1573403x1604201229115531>
- FDA. (2024, March 8). *FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight*. FDA. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or>
- Goyal, R., Jialal, I., & Singhal, M. (2023, June 23). *Type 2 diabetes*. National Center for Biotechnology Information; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK513253/>
- Hamley, I. W., de Mello, L. R., Castelletto, V., Zinn, T., Cowieson, N., Seitsonen, J., & Bizien, T. (2025). Semaglutide Aggregates into Oligomeric Micelles and Short Fibrils in Aqueous Solution. *Biomacromolecules*, 26(6), 3786–3794. <https://doi.org/10.1021/acs.biomac.5c00342>
- Heda, R., Tombazzi, C. R., & Toro, F. (2023, May 1). *Physiology, Pepsin*. National Library of Medicine; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK537005/>
- Jambhekar, S. S., & Breen, P. J. (2013). Drug dissolution: significance of physicochemical properties and physiological conditions. *Drug Discovery Today*, 18(23-24), 1173–1184. <https://doi.org/10.1016/j.drudis.2013.08.013>

- Juarez, D. T., Ma, C., Kumasaka, A., Shimada, R., & Davis, J. (2014). Failure to Reach Target Glycated A1c Levels Among Patients with Diabetes Who Are Adherent to Their Antidiabetic Medication. *Population Health Management*, 17(4), 218–223. <https://doi.org/10.1089/pop.2013.0099>
- Khan, F., Hussain, T., Chaudhry, T. Z., Payal, F., Shehryar, A., Rehman, A., Ramadhan, A., Hayat, M. T., Dabas, M. M., & Khan, M. (2024). Comparing the Efficacy and Long-Term Outcomes of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Metformin, and Insulin in the Management of Type 2 Diabetes Mellitus. *Cureus*. <https://doi.org/10.7759/cureus.74400>
- Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. *Frontiers in Endocrinology*, 10(155). <https://doi.org/10.3389/fendo.2019.00155>
- Kommu, S., & Whitfield, P. (2024, February 11). *Semaglutide*. PubMed; StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK603723/>
- Kulthe, Dr. V. V., Kshirsagar, G. M., & Sinha, A. R. (2025). Effect of Microcrystalline Cellulose Particle Size on Flowability and Compressibility in Direct Compression Method. *International Journal of Pharmacy and Pharmaceutical Research*, 31(12), 221–229. <https://doi.org/10.25166/ijppr.2025.31.12.22>
- Lu, Y., Tang, N., Lian, R., Qi, J., & Wu, W. (2014). Understanding the relationship between wettability and dissolution of solid dispersion. *International Journal of Pharmaceutics*, 465(1-2), 25–31. <https://doi.org/10.1016/j.ijpharm.2014.02.004>
- Markl, D., & Zeitler, J. A. (2017). A Review of Disintegration Mechanisms and Measurement Techniques. *Pharmaceutical Research*, 34(5), 890–917. <https://doi.org/10.1007/s11095-017-2129-z>
- Mahapatra, M. K., Karuppasamy, M., & Sahoo, B. M. (2022). Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes. *Reviews in*

Endocrine and Metabolic Disorders, 23(3), 521–539.

<https://doi.org/10.1007/s11154-021-09699-1>

McCartney, F., Gleeson, J. P., & Brayden, D. J. (2016). Safety concerns over the use of intestinal permeation enhancers: A mini-review. *Tissue Barriers*, 4(2), e1176822. <https://doi.org/10.1080/21688370.2016.1176822>

Meloni, A. R., DeYoung, M. B., Lowe, C., & Parkes, D. G. (2012). GLP-1 receptor activated insulin secretion from pancreatic β -cells: mechanism and glucose dependence. *Diabetes, Obesity and Metabolism*, 15(1), 15–27. <https://doi.org/10.1111/j.1463-1326.2012.01663.x>

Moonwiriyaakit, A., Pathomthongtaweethai, N., Steinhagen, P. R., Chantawichitwong, P., Satianrapapong, W., & Pongkorpasakol, P. (2022). Tight junctions: from molecules to gastrointestinal diseases. *Tissue Barriers*, 11(2). <https://doi.org/10.1080/21688370.2022.2077620>

National Center for Biotechnology Information. (2026a). *Decanoic acid*. Pubchem.ncbi.nlm.nih.gov. <https://pubchem.ncbi.nlm.nih.gov/compound/Decanoic-acid>

National Center for Biotechnology Information. (2026b). *Semaglutide*. Pubchem.ncbi.nlm.nih.gov. <https://pubchem.ncbi.nlm.nih.gov/compound/Semaglutide>

Novo Nordisk. (2019). *Rybelsus*. www.rybelsus.com. <https://www.rybelsus.com/>

Overgaard, R. V., Navarria, A., Ingwersen, S. H., Bækdal, T. A., & Kildemoes, R. J. (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. *Clinical Pharmacokinetics*, 60(10), 1335–1348. <https://doi.org/10.1007/s40262-021-01025-x>

Pawar, S. S., Rasal, P. B., Kulkarni, K. H., & Pawar, S. B. (2025). Semaglutide: A Comprehensive Review of its Pharmacology, Clinical Applications, and Future Therapeutic Potential. *Journal of Drug Delivery and Therapeutics*, 15(12), 103–114. <https://doi.org/10.22270/jddt.v15i12.7452>

Puckhaber, D., Finke, J. H., David, S., Gururajan, B., Rane, S., & Kwade, A. (2024). Effect of particle size on the dispersion behavior of magnesium stearate blended with microcrystalline cellulose.

<https://doi.org/10.1016/j.ijpharm.2024.123792>

Quodbach, J., & Kleinebudde, P. (2015). A Critical Review on Tablet Disintegration. *Pharmaceutical Development and Technology*, 21(6), 1–12. <https://doi.org/10.3109/10837450.2015.1045618>

Rabbani, N., & Thornalley, P. J. (2024). Unraveling the impaired incretin effect in obesity and type 2 diabetes: Key role of hyperglycemia-induced unscheduled glycolysis and glycolytic overload.

Diabetes Research and Clinical Practice, 217, 111905.

<https://doi.org/10.1016/j.diabres.2024.111905>

Rosenberg, J., Jacob, J., Desai, P., Park, J., Donovan, L., & Kim, J. Y. (2021). Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes. *Journal of Obesity & Metabolic Syndrome*, 30(3), 233–247. <https://doi.org/10.7570/jomes21053>

Sagala, R. J. (2019). Review: Metode Peningkatan Kecepatan Disolusi Dikombinasi Dengan Penambahan Surfaktan. *Jurnal Farmasi Galenika (Galenika Journal of Pharmacy) (E-Journal)*, 5(1), 84–92. <https://doi.org/10.22487/j24428744.2019.v5.i1.12360>

Sarkar, S., Ooi, S. M., Liew, C. V., & Wan, P. (2015). Influence of Rate of Force Application During Compression on Tablet Capping. *Journal of Pharmaceutical Sciences*, 104(4), 1319–1327.

<https://doi.org/10.1002/jps.24328>

Solis-Herrera, C., Kane, M. P., & Triplitt, C. (2023). Current Understanding of Sodium N-(8-[2-Hydroxybenzoyl] Amino) Caprylate (SNAC) as an Absorption Enhancer: The Oral Semaglutide Experience. *Clinical Diabetes*, 42(1). <https://doi.org/10.2337/cd22-0118>

Sorli, C., Harashima, S., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. *The Lancet Diabetes & Endocrinology*, 5(4), 251–260. [https://doi.org/10.1016/s2213-8587\(17\)30013-x](https://doi.org/10.1016/s2213-8587(17)30013-x)

- Sun, S., Liu, Y.-T., Nie, J.-Y., Hu, Z.-Y., Liu, Z.-R., Chen, H., Hua, Y., Feng, S., Yi, T., & Zhang, J.-F. (2025). Advances and challenges in research methods on oral absorption mechanisms of nano-formulations. *PeerJ*, 13, e20032. <https://doi.org/10.7717/peerj.20032>
- Suna, S. (2025). Liquid Penetration Testing in Commercialized Tablets. *Journal of Research in Pharmaceutical Science*, 11(3), 47–53. <https://doi.org/10.35629/2995-11034753>
- Twarog, C., Fattah, S., Heade, J., Maher, S., Fattal, E., & Brayden, D. J. (2019). Intestinal Permeation Enhancers for Oral Delivery of Macromolecules: A Comparison between Salcaprozate Sodium (SNAC) and Sodium Caprate (C10). *Pharmaceutics*, 11(2), 78. <https://doi.org/10.3390/pharmaceutics11020078>
- Vélez, L. A., Delgado, Y., Ferrer-Acosta, Y., Suárez-Arroyo, I. J., Rodríguez, P., & Pérez, D. R. (2022). Theoretical Prediction of Gastrointestinal Absorption of Phytochemicals. *International Journal of Plant Biology*, 13(2), 163–179. <https://doi.org/10.3390/ijpb13020016>
- Wu, J., Liu, D., Feng, C., Luo, Y., Nian, Y., Wang, X., & Zhang, J. (2018). The Characteristics of Postprandial Proximal Gastric Acid Pocket in Gastroesophageal Reflux Disease. *Medical Science Monitor : International Medical Journal of Experimental and Clinical Research*, 24, 170–176. <https://doi.org/10.12659/MSM.904964>
- Yang, X.-D., & Yang, Y.-Y. (2024). Clinical Pharmacokinetics of Semaglutide: A Systematic Review. *Drug Design Development and Therapy*, Volume 18, 2555–2570. <https://doi.org/10.2147/dddt.s470826>
- Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024). Glucagon-like peptide-1 receptor: Mechanisms and Advances in Therapy. *Signal Transduction and Targeted Therapy*, 9(1), 1–29. <https://doi.org/10.1038/s41392-024-01931-z>